February 15, 2008
OncoGenex Reports Lead Drug Candidate OGX-011 Achieved Primary Endpoint in Phase 2 Trial with Second-Line Chemotherapy for Prostate Cancer

February 11, 2008
Presidio Pharmaceuticals and Numerate Announce Research Collaboration to Identify Improved Hepatitis C Therapeutics

January 7, 2008
Mr. Leo Redmond Joins Presidio Pharmaceuticals as Chief Financial Officer

December 10, 2007
Celator® Pharmaceuticals Reports CPX-351 Shows Anti-Cancer Activity in Leukemia Patients

October 26, 2007
Celator® Pharmaceuticals Study Shows CPX-571 Maintains Synergistic Ratio of Irinotecan and Cisplatin to Improve Anti-tumor Activity

October 18, 2007
Lilly and MacroGenics Announce Licensing and Collaboration Agreement

September 26, 2007
Jeffrey H. Buchalter Joins Macrogenics Board of Directors as Chairman

September 18, 2007
Presidio Pharmaceuticals Adds Industry Veteran Dr. Richard Colonno as Chief Scientific Officer

August 14, 2007
NeurAxon Announces Positive Phase 1 Trial Data on NXN-188 for Migraine

August 7, 2007
NeurAxon Appoints Robert Medve, M.D., as Chief Medical and Regulatory Officer

July 31, 2007
NeurAxon Appoints Lawrence E. Bloch, M.D., J.D., as Chief Executive Officer

June 4, 2007
Study Presented at ASCO Shows Encouraging One-Year and Overall Survival Results for Phase I/II Trial of OGX-011 in Non-Small Cell Lung Cancer

May 23, 2007
Resonant Medical announces new CEO, VP Strategic Marketing and Chairman of the Board of Directors

May 11, 2007
Novadaq Increases Private Placement to Approximately $30 Million

March 13, 2007
Caprion and Ecopia complete combination and announce closing of $45 million private placement

January 4, 2007
Ecopia Announces Agreement with Caprion to Combine Their Businesses and Launch a $30 Million Private Placement

January 3, 2007
MacroGenics and JDRF Form Partnership to Support Pivotal Phase II/III Clinical Trial of Anti-CD3 Monoclonal Antibody for Children and Adults with Recent-Onset Type 1 Diabetes

December 7, 2006
Xenon Enters into Anemia Collaboration with Roche

October 2, 2006
Xenon and Takeda Announce Agreement To Develop and Commercialize XEN401 for Pain in Japan and Certain Asian Countries

October 2, 2006
MacroGenics Receives Multiple Government Awards Totaling More Than $62 Million to Advance Infectious Disease Programs

August 7, 2006
Celator Pharmaceuticals Names Dr. Arthur C. Louie as New Chief Medical Officer

July 31, 2006
J. Kevin Buchi Joins the Celator Pharmaceuticals Board of Directors

July 17, 2006
Celator Pharmaceuticals Announces Positive European Patent Decision for Combiplex™ Technology Used To Develop Fixed-Ratio Combination Chemotherapies

May 10, 2006
Caprion Receives FDA Fast Track Designation for Shigamabs Clinical Program

May 5, 2006
Caprion Pharmaceuticals Inc. Files for Initial Public Offering

May 3, 2006
OncoGenex Announces Encouraging Data from a Phase I Study of Patients with Non-Small Cell Lung Cancer

May 2, 2006
Varian Medical Systems and Resonant Medical Settle Outstanding Litigation

April 11, 2006
Xenon Raises US$31 Million in Private Financing

March 14, 2006
Caprion Pharmaceuticals Announces the Acquisition of a Novel Therapeutic Peptide with Broad Applicability in Oncology

February 14, 2006
OncoGenex Appoints New CFO and Board Member

January 10, 2006
Caprion Pharmaceuticals Enters Into Oncology Target Licensing Agreement with ImClone Systems